Greece's National Organisation for Medicines (EOF) on Wednesday announced that it is recalling two lines of widely used heartburn medication containing the drug ranitidine, over fears that production lines have been contaminated with the potential carcinogen N-nitrosodimethylamine, or NDMA.
The move follows similar action taken by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) after tainted batches of the drugs were confirmed.
The drugs were sold in Greece under the trade names ZANTACEF.TAB 150MG/TAB, ZANTAC F.C.TAB 150MG/TAB and ZANTAC INJ.SOL 50MG/2ML AMP, by the pharmaceutical company GLAXOSMITHKLINE ΑΕΒΕ, and the generic drug RANITIDINE/MYLAN F.C.TAB 150MG/TAB sold by GENERICS PHARMA HELLAS ΕΠΕ.